2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4099 Epitope-edited allogeneic CD2 CAR-T (UCART2edit) for T cell malignancies

Jingyu Xiang, MD, MSCI, Michael P. Rettig, PhD2, Julie Ritchey3, Stacey Kang4, Yalda Karamlou5, Matthew Cooper, PhD6, John F. DiPersio, MD7
1 Washington University in St. Louis, St. Louis, Missouri, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Washington University in St. Louis, St. Louis, Missouri, United States
4 Washington University in St. Louis, St. Louis, Missouri, United States
5 Washington University in St. Louis, St. Louis, Missouri, United States
6 Washington University in St. Louis, St. Louis, Missouri, United States
7 Washington University in St. Louis, St. Louis, Missouri, United States

INTRODUCTION: T-cell malignancies are associated with frequent relapse and high morbidity in children and adults, partly due to the lack of effective or targeted treatment options. Despite the use of multidrug chemotherapy, <50% of adults and <75% of children with T-ALL survive longer than five years. In addition, the 3-year overall survival of relapsed and refractory T-ALL and T-NHL patients is <20%. While CAR-T cell therapy is remarkable in treating B-cell malignancies, its use in T-cell malignancies is restricted due to fratricide, risk of immunodeficiency, immune escape, and allorejection. CD2 is expressed on >99% of T-cells and is downregulated at a lower frequency than other pan-T cell markers in cancer cells, providing an attractive therapeutic target. To broaden the use of CAR-T cells in pan T-cell malignancies, we recently developed an allogeneic “universal” CD2-targeting CAR-T (UCART2KO), in which CD2 and the T-cell receptor alpha (TRAC) subunit are deleted by CRISPR/Cas9 editing to prevent both fratricide and GvHD. However, due to the important role of the CD2:CD58 axis in T-cell function, CD2 deletion led to reduced CAR-T efficacy in vivo.

METHODS: To validate whether CD2 epitope disruption could prevent Siplizumab binding to CD2, we generated constructs expressing previously defined CD2 epitope mutations. To install the CD2 epitope mutations in primary cells, we used a novel “Spacer-nick” gene correction approach that combines Cas9D10A nickase/PAM-out sgRNAs and Adeno-associated virus serotype 6 (AAV6) template to mediate precise epitope editing. A pair of sgRNAs targeting TRAC was delivered to allow simultaneous deletion of the TRAC gene to prevent GvHD. CD58-Fc binding assay was performed by incubating UCART2KO or UCART2edit with recombinant CD58-Fc chimera protein, followed by FACS detection using a PE-conjugated anti-human Fc IgG antibody. In vitro CAR-T function of UCART2edit was evaluated using a serial tumor re-challenge assay with Jurkat (human T-ALL). In vivo efficacy of UCART2KO vs. UCART2edit was assessed using the HHCBR-GFP CTCL and T-ALL PDX models in NSG mice. CART19 function was assessed against CD19+ Nalm6 tumor cells using a chronic stimulation assay in vitro.

RESULTS: To overcome the attenuated CAR-T function due to CD2 loss, we developed a novel epitope-edited allogeneic CD2-targeting CAR-T (UCART2edit), in which the human CD2 binding epitopes of siplizumab (a humanized anti-CD2 IgG1k monoclonal antibody tested in Phase I/II clinical trials) are mutated on CAR-T cells via CRISPR/Cas9 gene editing technology to prevent fratricide. We found that incorporating the CD2 epitope mutations into CD2 completely abrogated Siplizumab binding to CD2 without interfering with the normal CD2:CD58 axis and function in primary T cells. Using a novel “Spacer-nick” based CRISPR/Cas9+AAV6 gene correction approach, we achieved multiplex CD2 epitope editing (70-80% HDR-mediated knock-in) and TRAC KO (90-95% efficiency) in primary T cells. CD2 epitope masking generates CAR-T cells that are fratricide-resistant. During manufacturing, UCART2edit showed similar expansion as UCART2KO and had similar in vitro killing efficacy in the 24-hour killing assay. However, following serial re-challenge with Jurkat T-ALL cells, UCART2edit demonstrated significantly enhanced CAR-T expansion, tumor clearance capacity, and persistence in vitro compared to UCART2KO. In addition, UCART2edit produced higher levels of IFN-𝛾 and IL-2 in response to CD2+ tumor cells. Consistent with these findings, UCART2edit showed greater efficacy against HHCBR/GFP CTCL and T-ALL PDX tumors and prolonged survival in vivo. Finally, CD2 epitope-edited CART19 rescued the loss of function observed in CD2 KO CART19, achieving CAR-T expansion and killing comparable to WT CART19.

CONCLUSIONS: We have developed an allogeneic epitope-edited CD2 CAR-T cell (UCART2edit) using a novel “Spacer-nick” based CRISPR/Cas9 gene editing approach: CD2 epitope masking prevents Siplizumab binding without interrupting the normal CD2:CD58 axis and generates CAR-T cells with functional CD2 without fratricide. Compared to UCART2KO, UCART2edit demonstrated significantly enhanced CAR-T expansion, tumor clearance, and persistence. Consistently, UCART2edit showed enhanced in vivo anti-tumor efficacy and prolonged survival in vivo. Together, our data demonstrate that the CD2 epitope-edited UCART2edit could serve as a promising therapy for pan-T-cell malignancies.

Jingyu Xiang, MD, MSCI: No relevant conflicts of interest to declare.